Applications of CRISPR-Cas9 Genome Editing Technology in the Treatment of Human Diseases
International Journal of High School Research · 30.05.2026 · 8 (10) · 19-30
DOI: 10.36838/ijhsr810.19 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of High School Research, online erschienen am 30.05.2026. Verfasst von Elif Baser.
Abstract (Originalsprache)
Genome editing (GED) technologies have advanced substantially and are currently being tested for the treatment of human diseases.Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) GED technology has advanced biotechnology by providing a relatively simple and cost-effective method for creating precise deoxyribonucleic acid edits compared to other GED technologies.This technology has become a promising method for treating diseases by enabling the targeted disruption, modification, or editing of pathogenic genes.However, several factors, including disease heterogeneity, off-target effects, and technical and ethical challenges in its application, limit the clinical use of CRISPR-Cas9.This article examines the therapeutic efficacy of CRISPR-Cas9 technologies in the treatment of numerous conditions, including cancer, neurodegenerative diseases, viral infections, allergic and immunological diseases, and hematologic diseases.
Zitieren
APA
Baser, E. (2026). Applications of CRISPR-Cas9 Genome Editing Technology in the Treatment of Human Diseases. International Journal of High School Research, 8(10), 19-30. https://doi.org/10.36838/ijhsr810.19
Vancouver
Baser E. Applications of CRISPR-Cas9 Genome Editing Technology in the Treatment of Human Diseases. International Journal of High School Research. 2026;8(10):19-30. doi:10.36838/ijhsr810.19
BibTeX
@article{Baser2026,
author = {Baser, Elif},
title = {Applications of CRISPR-Cas9 Genome Editing Technology in the Treatment of Human Diseases},
journal = {International Journal of High School Research},
year = {2026},
volume = {8},
number = {10},
pages = {19--30},
doi = {10.36838/ijhsr810.19}
}
EUVIMED